Patent Claims

1. Compounds of the formula I

5

10

in which

R¹ is H, A, benzyl, indan-5-yl, 1,2,3,4-tetrahydronaphthalen-5-yl, dibenzothien-2-yl, or phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, A-CO-NH, benzyloxy, alkoxy, COOH or COOA,

 R^2 is H or A,

X is O or S,

Hal is F, Cl, Br or I,

A is alkyl with 1 to 6 C atoms, and the physiologically acceptable salts and/or solvates thereof as phosphodiesterase VII

inhibitors.

20

25

- 2. Pharmaceutical preparation characterized by a content of at least one phosphodiesterase VII inhibitor of the formula I according to claim 1 and/or one of its physiologically acceptable salts and/or one of its solvates.
- 3. Use of compounds of the formula I according to claim 1 and/or their physiologically acceptable salts or solvates for producing a pharmaceutical 30 controlling allergic disorders, asthma. chronic bronchitis, atopic dermatitis, psoriasis and other skin disorders, inflammatory disorders, autoimmune diseases such as, for example rheumatoid arthritis, multiple sclerosis, Crohn's

disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disturbances, atherosclerosis and AIDS.

4. Use of phosphodiesterase VII inhibitors for producing a pharmaceutical for controlling allergic disorders, asthma, chronic bronchitis, 10 atopic dermatitis, psoriasis and other disorders, inflammatory disorders, autoimmune diseases such as, for example rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative 15 osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disturbances, atherosclerosis and AIDS.

5